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GR43175, a selective 5-HT,-like agonist, was administered as oral dispersible tablets in an 
open, uncontrolled dose-ranging study to assess its efficacy as an agent for acute migraine. 
Nine patients, all with well established attacks, were assessed for changes in severity of 
headache and associated symptoms over 2 h. Drug absorption was compared during and 
between attacks in five patients. Doses of 140 mg and 280 mg resulted in complete relief of 
all symptoms within 2 h. Treatment was well tolerated in all patients. 0 GR4317.5, dispersible 
tablets, acute migraine, absorption 
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In a series of dose-ranging studies with par- 
enteral formulations GR43175 appeared 
effective in aborting well established, acute 
common or classical migraine attacks within 
20-30 min. A single intravenous infusion of 
2 mg over 10 min (1) or subcutaneous injec- 
tion of 3 mg or 4 mg (2,3) gave the most 
consistent results. Volunteer studies (4) with 
a dispersible tablet indicated that this may 
represent a suitable non-parenteral route of 
administration. 
Subjects and methods 
Previously identified patients aged between 
18 and 60 years with a known history of 
common or classical migraine who were 
attending a pain clinic were eligible for the 
study. (Common migraine is defined as: 
recurrent, episodic severe headache, often 
unilateral and accompanied by anorexia, 
nausea and/or vomiting but without striking 
prodromes. Classical migraine is defined as: 
similar to the above but preceded by defined 
transient visual, and other sensory or motor 
prodromes.) Consenting patients were asked 
to attend at the time of their next migraine 
attack if symptoms were not improving. 
Pregnant or breast-feeding women were 
excluded as were those patients with a his- 
tory of ischaemic heart disease, chest pain, 
hypertension or serious systemic disease. To 
ensure that changes in migraine symptoms 
were not a result of previous medication, 
recent use of ergotamine (within 24h) or 
simple analgesics such as aspirin (within 6 h) 
was prohibited. 
All migraine symptoms were graded by 
the patient using simple rating scales for 
severity of headache ( 3  = severe, 2 = mod- 
erate, 1 = mild, 0 = none) the degree of 
functional disability (3 = requiring bedrest, 
2 = working ability severely impaired, 1 = 
working ability slightly impaired, 0 = func- 
tioning normally), and presence or absence 
of associated symptoms (nausea, vomiting, 
photophobia). Serial pulse, blood pressure 
and ECG recordings were made with the 
patient supine. A small cannula was inserted 
in a dorsal forearm vein for withdrawal of 
blood. 
The tablets (35 mg) were dispersed in 
100 ml of tap water before administration. 
Doses of 70mg, 140mg and 280mg were 
administered to separate patients. 
Migraine symptoms were assessed at base- 
line, 1, 1.5 and 2 h. Patients not responding 
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at 2 h were offered rescue medication with- 
out ergotamine. Blood pressure, pulse, ECG 
recordings and plasma samples (for drug 
assay) were taken at 1, 1 .5 ,2 ,3  and 4 h after 
treatment. Blood samples were taken before 
and after treatment for routine haema- 
tological and biochemical analyses. 
All patients were observed for a minimum 
of 4 h  before they were allowed to leave 
the clinic. They were asked to report any 
untoward symptoms at any time during or 
following GR43175 administration. 
2 hr following 
GR43 175 
-- - 280 mg 
No. of patients 
with nausea 




line represents one 
patient. Headache 
severity grade: 3 = 
severe; 2 = moderate; 
1 = mild; 0 = none. 
Results 
Nine patients (8F, 1M; mean age 42.3 years; 
range 2 3 4 0  years) all with common migraine 
werb .rested. Mean duration of their attacks 
before treatment was 6 h 23 min (range 55 
min to 16 h 45 min). Before treatment eight 
(88%) patients had severe headache (grade 
3) and seven (77%) were nauseated; no 
patients were vomiting. All either required 
bedrest or were unable to work normally. 
Although the number of patients in the 
study was small there appeared to be a dose- 
related improvement in migraine symptoms. 
Doses of 140 mg or 280 mg gave complete 
headache relief (grade 0) within 2 h (Fig. 1) 
Pretreatment 1 1.5 2 hours 
following 
GR43 175 
Fig. 2. Effects of GR43175 (oral) on nausea. (One 
additional patient treated with 280 mg GR43175 showed 
relief of nausea after 1 h.) 
and associated symptoms (nausea, photo- 
phobia) had resolved by 1.5 h (Fig. 2). This 
was reflected by an overall improvement in 
clinical disability: in all cases patients felt 
able to function normally (grade 0) by 1.5 h 
(Table 1). 
In comparison, only one of those patients 
receiving 70 mg had complete headache 
relief within 2 h. Of the remaining patients 
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Table 1. Effects of GR43175 on clinical disability. 
Clinical disability 
Dose Total no. Time 
(mg) of patients (h) 3 2 1 0 
70 4 Before 1 3 0 0 
1 1 0 2 1 
1 .5 0 1 2 1 
2 0 1 1 2 
140 4 Before 2 2 0 0 
1 0 1 1 2 
1.5 0 0 1 3 
2 0 0 0 4 
280 1 Before 0 1 0 0 
1 0 0 1 0 
1.5 0 0 0 1 
2 0 0 0 1 
Clinical disability grading: 3 = requiring bedrest; 2 = working ability severely impaired; 1 = working ability 
impaired to some degree; 0 = able to work/function normally. 
two reported a mild residual non-migraine 
headache and one a moderately severe 
migraine headache. Associated symptoms 
(nausea and photophobia) resolved com- 
pletely within 2 h. This was reflected by a 
degree of improvement in overall clinical 
disability (Table 1). All doses of GR43175 
were well tolerated and no adverse events 
were reported. There was no noticeable or 
consistent change in pulse rates, ECG recor- 
dings or laboratory parameters attributable 
to GR43 175. 
Drug plasma determinations showed that 
symptom relief was obtained within the 
range 18-60 ng GR43175/ml plasma. Mean 
peak plasma concentrations of 31, 68 and 
136ng/ml were obtained with doses of 70, 
140 and 280 mg, respectively, suggesting that 
doubling the dose produces a corresponding 
doubling in the peak plasma concentration. 
Discussion 
Initial clinical experience with intravenous 
and subcutaneous GR43175 indicated that 
the drug may represent a fast, effective and 
well tolerated treatment for acute common 
and classical migraine. Whilst the subcu- 
taneous formulation represents a convenient 
parenteral form for use by medical person- 
nel, a non-parenteral formulation would 
be more convenient for patient self- 
administration. 
An oral preparation in the form of a 
dispersible tablet was tested in healthy 
volunteers. Pharmacokinetic data indicated 
relatively rapid absorption, peak plasma 
concentrations being reached within 2 h. 
However, the degree of absorption of an oral 
formulation during a migraine attack, when 
nausea and vomiting often accompany the 
headache and gastric motility is known to be 
reduced, was uncertain. 
This preliminary clinical study indicated 
good absorption of oral GR43175 in well 
established acute migraine attacks, despite 
the presence of nausea in most patients. Peak 
plasma concentrations similar to the pro- 
posed therapeutic range from intravenous 
dosing were obtained within 40-120 min. 
Migraine headache and associated symp- 
toms were rapidly resolved with the higher 
doses without affecting heart rate, blood 
pressure or ECG recording. No adverse 
effects were reported in this study. 
The oral formulation seems to provide a 
suitable non-parenteral alternative. Further 
placebo-controlled studies, however, are 
required to confirm these early findings. 
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